29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria

Key Takeaways Explain This Topic AI

Group A Streptococcus (GAS / Streptococcus pyogenes) causes only 5% to 15% of acute pharyngitis in adults and 15% to 30% in children aged 3 to 14 years; viral pathogens account for the overwhelming majority of cases, making cough, coryza, hoarseness, and oral ulcerations reliable clinical markers to rule OUT bacterial testing.

The Modified Centor (McIsaac) score assigns 1 point each for fever >38.0°C (100.4°F), absence of cough, tender anterior cervical lymphadenopathy, and tonsillar exudate/swelling, adjusted for age (+1 for 3-14y, 0 for 15-44y, -1 for >=45y); scores <=1 require NO diagnostic testing and NO antibiotics, whereas scores >=2 warrant rapid antigen detection testing (RADT).

In pediatric patients and adolescents (<18 years), a negative RADT mandates a reflexive backup throat culture to prevent missed cases of Acute Rheumatic Fever; in adults (>=18 years), backup throat culture is not recommended because ARF is extraordinarily rare and culture identifies asymptomatic carrier states.

First-line therapy for confirmed GAS pharyngitis is oral Penicillin V (500 mg BID-TID for 10 days) or Amoxicillin (500 mg BID or 1,000 mg once daily for 10 days); cephalexin is the preferred alternative for non-anaphylactic penicillin allergies, whereas severe IgE-mediated anaphylaxis mandates azithromycin or clindamycin.

Antibiotic treatment initiated within 9 days of symptom onset reliably prevents Acute Rheumatic Fever (ARF, diagnosed by the revised Jones criteria), but antibiotics do NOT prevent Post-Streptococcal Glomerulonephritis (PSGN), which presents 1 to 3 weeks later with cola-colored urine, hypertension, and periorbital edema.

Last updated: September 2026

Epidemiology & Etiologic Spectrum of Acute Pharyngitis

Acute pharyngitis is one of the most frequent chief complaints encountered in primary care, accounting for approximately 12 million ambulatory visits annually in the United States. Although pharyngitis prompts substantial patient anxiety regarding 'strep throat', the clinical reality is that the vast majority of acute sore throats across all age groups are caused by self-limited viral respiratory pathogens .

Epidemiological Distribution

Children Aged 3 to 14 Years : Group A beta-hemolytic Streptococcus ( Streptococcus pyogenes , GAS) accounts for 15% to 30% of acute pharyngitis cases. This represents the peak epidemiological demographic for streptococcal disease.

Adults (>=15 Years) : GAS accounts for only 5% to 15% of adult pharyngitis presentations; more than 85% to 90% of adult sore throats are viral.

Children Younger Than 3 Years : GAS pharyngitis is distinctly uncommon (<5%), and when present, manifests atypical symptoms ('streptococcosis': chronic mucopurulent rhinorrhea, low-grade fever, excoriated nares, and generalized adenopathy). Because Acute Rheumatic Fever is virtually unheard of in children under 3 years of age , diagnostic testing for GAS is strictly not indicated in this age group unless a household sibling has confirmed GAS. ETIOLOGY OF ACUTE PHARYNGITIS BY AGE

Children (3-14 Years) Adults (>=15 Years)
┌───────────────────────────┐ ┌───────────────────────────┐
│ Viral (~70-85%) │ │ Viral (>85-90%) │
│ • Rhinovirus, Adeno, │ │ • Rhinovirus, Corona, │
│ Entero, EBV, Parainfl. │ │ Adeno, Influenza, EBV │
├───────────────────────────┤ ├───────────────────────────┤
│ GAS / S. pyogenes │ │ GAS / S. pyogenes │
│ (15% to 30%) │ │ (5% to 15%) │
├───────────────────────────┤ ├───────────────────────────┤
│ Other Bacteria (<5%) │ │ Other Bacteria (<5%) │
│ • Groups C/G Strep │ │ • F. necrophorum, C/G, │
│ • M. pneumoniae │ │ N. gonorrhoeae │
└───────────────────────────┘ └───────────────────────────┘
Viral Etiologies & The Clinical 'Viral Signature'

In viral pharyngitis, inflammatory damage to the pharyngeal mucosa is mediated by viral replication and cytotoxic cytokine release. Specific viral pathogens produce distinctive physical examination findings:

Rhinovirus and Coronavirus : Mild pharyngeal erythema accompanied by prominent sneezing, clear rhinorrhea, and nasal congestion.

Adenovirus : Causes pharyngoconjunctival fever , marked by prominent pharyngitis, high fevers, follicular non-purulent conjunctivitis, and preauricular lymphadenopathy.

Enteroviruses (Coxsackievirus A) : Produces herpangina —abrupt onset of high fever, sore throat, and classic 1- to 2-mm grayish-white papulovesicular lesions that rupture into shallow, painful ulcers with erythematous halos localized to the soft palate, uvula, and anterior tonsillar pillars (the posterior pharynx and gingiva are spared). Also causes Hand-Foot-and-Mouth disease.

Epstein-Barr Virus (EBV) : The primary agent of infectious mononucleosis , characterized by profound tonsillar enlargement covered by shaggy white-gray exudates, palatal petechiae, fever, symmetric posterior cervical lymphadenopathy , and splenomegaly.

Herpes Simplex Virus (HSV-1) : Primary gingivostomatitis presenting with friable, bleeding gums and vesicular ulcerations involving the anterior oral cavity, hard palate, and lips.

Acute Retroviral Syndrome (Primary HIV) : Manifests 2 to 4 weeks post-exposure as a mononucleosis-like illness with pharyngeal erythema (often non-exudative), shallow painful mucocutaneous ulcerations, generalized non-tender lymphadenopathy, fever, arthralgias, and a non-pruritic maculopapular rash on the trunk.

Tip

The 'Viral Signature' Rule : The presence of cough, rhinorrhea/coryza, hoarseness, conjunctivitis, anterior oral mucosal ulcerations, or diarrhea points strongly to a viral upper respiratory infection. If these viral features are prominent, diagnostic testing for GAS (RADT or throat culture) should be withheld, as positive tests in this setting merely capture chronic asymptomatic streptococcal carriage.

Bacterial Pathogens Beyond Group A Streptococcus

Group C and Group G Streptococci : Large-colony beta-hemolytic streptococci that cause acute exudative pharyngitis clinically indistinguishable from GAS, frequently occurring in foodborne outbreaks or among college students. Crucially, Groups C and G do NOT cause Acute Rheumatic Fever, although they can trigger post-streptococcal glomerulonephritis.

Fusobacterium necrophorum : Anaerobic, pleomorphic Gram-negative rod increasingly recognized as an important cause of endemic pharyngitis in adolescents and young adults (ages 15 to 24). It is the primary etiologic agent of Lemierre syndrome (internal jugular vein septic thrombophlebitis).

Arcanobacterium haemolyticum : Gram-positive bacillus causing acute exudative pharyngitis in adolescents and young adults, accompanied by a scarlatiniform, fine maculopapular rash on the extensor surfaces of limbs that spares the face. Intrinsically resistant to penicillins; requires treatment with oral macrolides.

Neisseria gonorrhoeae : Gram-negative diplococcus acquired via orogenital contact; causes asymptomatic infection or severe pharyngeal erythema with cervical lymphadenopathy. Requires nucleic acid amplification testing (NAAT) or specialized Thayer-Martin culture; treated with intramuscular ceftriaxone.

Corynebacterium diphtheriae : Rare in vaccinated populations; produces a dense, tenacious, gray-black pseudomembrane firmly adherent to the tonsils, uvula, and soft palate that bleeds profusely on attempted dislodgement, accompanied by profound cervical soft tissue edema ('bull neck') and systemic toxin-mediated myocarditis and neuropathies.

The Modified Centor Criteria (McIsaac Score): Risk Stratification

Because clinical impression alone reliably overestimates the likelihood of streptococcal pharyngitis (clinicians prescribe antibiotics in >60% of pharyngitis visits despite a GAS prevalence of 10%), validated clinical decision rules are essential. The Centor criteria , initially formulated in emergency department adults, were modified by McIsaac to incorporate age adjustments, establishing the standard Modified Centor (McIsaac) score : MODIFIED CENTOR (McISAAC) SCORE

CLINICAL CRITERIA POINTS
──────────────────────────────────────────────────────────────────
1. History of documented fever (>38.0°C or 100.4°F) +1
2. Absence of cough +1
3. Tender anterior cervical lymphadenopathy +1
4. Tonsillar swelling or tonsillar exudates +1
──────────────────────────────────────────────────────────────────
AGE ADJUSTMENT
Age 3 to 14 years +1
Age 15 to 44 years 0
Age >=45 years -1
──────────────────────────────────────────────────────────────────
TOTAL POSSIBLE SCORE: -1 to 5 points
Evidence-Based Risk Stratification and Clinical Action

Total Score Estimated GAS Probability Clinical Action Protocol (IDSA / AAFP Guidelines)

Score <=1 2% to 6% NO diagnostic testing; NO antibiotic therapy .; Prescribe purely symptomatic management (analgesics, throat lozenges, warm salt water gargles). Testing is actively contraindicated.

Score 2 10% to 17% Perform Rapid Antigen Detection Test (RADT) .; Prescribe antibiotics ONLY if the RADT is positive. Backup culture if negative in pediatric patients.

Score 3 28% to 35% Perform Rapid Antigen Detection Test (RADT) .; Prescribe antibiotics ONLY if the RADT is positive. Backup culture if negative in pediatric patients.

Score >=4 51% to 53% Perform Rapid Antigen Detection Test (RADT) .; Treat only if positive. (Historically, empiric antibiotics were considered for score >=4; however, current IDSA guidelines mandate microbiological confirmation even at score >=4 because ~50% of these patients do NOT have GAS).

Diagnostic Testing Protocol: RADT & The Pediatric vs. Adult Divergence

To ensure rational antibiotic prescribing, clinical criteria must be coupled with point-of-care microbiological verification. DIAGNOSTIC ALGORITHM FOR SUSPECTED GAS

Modified Centor Score >=2
│
▼
Perform Throat Swab for RADT
(Vigorous Swab of Both Tonsils/Pillars)
│
┌───────────────┴───────────────┐
▼ ▼
RADT POSITIVE RADT NEGATIVE
│ │
▼ ▼

INITIATE ANTIBIOTICS Patient Age?

Oral Penicillin V ┌──────┴──────┐
Oral Amoxicillin ▼ ▼
Cephalexin (if allergic) Child <18y Adult >=18y
│ │
▼ ▼
MANDATORY BACKUP NO BACKUP
THROAT CULTURE CULTURE
│ │
Wait 48h; treat Symptomatic
only if positive Care Only
Rapid Antigen Detection Testing (RADT)

Mechanism : Utilizes enzymatic or acid extraction to isolate the Lancefield group A carbohydrate antigen from throat swabs, detected via sandwich immunoassay.

Performance : High specificity ( >=95% to 98% ), with moderate-to-high sensitivity ( 70% to 90% ).

Swabbing Technique : The sterile Dacron or Rayon swab must vigorously sample both palatine tonsils (or tonsillar fossae) and the posterior pharyngeal wall , specifically swabbing areas of purulence or ulceration. Contact with the tongue, uvula, buccal mucosa, or lips must be avoided to prevent saliva contamination and false negatives.

The Critical Board Divergence: Backup Throat Cultures

Pediatric Patients and Adolescents (<18 Years) : A negative RADT MUST be reflexively followed by a backup throat culture (inoculated onto 5% sheep blood agar). Rationale : Because the sensitivity of point-of-care RADT is imperfect (~70-90%), up to 10% to 30% of true GAS cases could be missed. In children, untreated GAS carries a tangible risk of triggering Acute Rheumatic Fever (ARF) . A backup throat culture ensures that false-negative RADTs are detected and treated within the 9-day therapeutic window for ARF prevention.

Adult Patients (>=18 Years) : A negative RADT does NOT require a backup throat culture . Rationale : The incidence of Acute Rheumatic Fever in adults in developed nations is virtually zero (<1 case per million). Furthermore, throat cultures in adults frequently identify low-inoculum asymptomatic GAS carriage (which affects 5% to 10% of the healthy adult population), resulting in unnecessary antibiotic exposure. A negative RADT in an adult rules out GAS for clinical purposes.

Evidence-Based Antimicrobial Therapy for GAS Pharyngitis
Therapeutic Objectives

Antimicrobial treatment of confirmed GAS pharyngitis is directed toward four distinct clinical goals:

Prevention of Acute Rheumatic Fever : The paramount public health objective. Complete prevention is achieved as long as antibiotics are initiated within 9 days of symptom onset.

Shortening Symptom Duration : Hastens clinical resolution of fever, throat pain, and dysphagia by approximately 1 to 2 days compared to placebo.

Prevention of Suppurative Complications : Dramatically reduces the incidence of peritonsillar abscess, retropharyngeal abscess, suppurative cervical lymphadenitis, sinusitis, and otitis media.

Interruption of Transmission : Eradicates viable GAS from the pharynx within 24 hours. Patients are considered non-contagious and may return to school or work after 24 hours of effective antibiotic therapy provided they are afebrile.

First-Line Antimicrobial Regimens

Streptococcus pyogenes has maintained 100% universal susceptibility to beta-lactam antibiotics; clinical penicillin resistance has never been documented anywhere in the world. GAS ANTIMICROBIAL DOSING PROTOCOLS

ORAL PENICILLIN V (Gold Standard)
Adults: 500 mg PO BID or TID for 10 days
Children: 250 mg PO BID or TID for 10 days

ORAL AMOXICILLIN (Pediatric Preferred - Palatable Suspension)
Adults: 500 mg PO BID or 1,000 mg PO once daily for 10 days
Children: 50 mg/kg PO once daily (max 1,000 mg) for 10 days

INTRAMUSCULAR BENZATHINE PENICILLIN G (Single Injection)
Weight >=27 kg / Adults: 1,200,000 units IM single dose
Weight <27 kg: 600,000 units IM single dose
Ideal for non-compliance, emesis, or personal/family history of ARF
Management of the Penicillin-Allergic Patient

Antimicrobial choice depends strictly on whether the allergy was a non-severe cutaneous reaction or a severe, life-threatening IgE-mediated anaphylactic reaction:

Non-Anaphylactic / Non-IgE Allergy (e.g., mild maculopapular rash without hives or systemic symptoms) :

First-Generation Cephalosporin : Cephalexin 20 mg/kg/dose PO BID (max 500 mg BID) for 10 days , or Cefadroxil 30 mg/kg once daily (max 1,000 mg) for 10 days.

Cross-reactivity between penicillins and first-generation cephalosporins is extremely low (<1% to 2% in modern formulations lacking ampicillin side-chain similarities), making cephalexin highly effective, safe, and bactericidal.

Severe IgE-Mediated Allergy (Anaphylaxis, Angioedema, Bronchospasm, Immediate Urticaria) :

All beta-lactams (including all cephalosporins) are strictly contraindicated .

Azithromycin : 12 mg/kg PO once daily (max 500 mg) on day 1, followed by 6 mg/kg once daily (max 250 mg) on days 2 through 5 (5-day course).

Clarithromycin : 15 mg/kg/day PO divided BID (max 250 mg BID) for 10 days.

Clindamycin : 20 mg/kg/day PO divided TID (max 300 mg TID) for 10 days. Clindamycin is particularly useful in recurrent GAS or carriage states due to excellent tissue penetration and inhibition of streptococcal pyrogenic exotoxin synthesis.

Caveat on Macrolides : Approximately 5% to 15% of GAS isolates in the United States exhibit macrolide resistance mediated by erm or mef genes; macrolides must be reserved strictly for severe beta-lactam allergies.

Non-Suppurative Post-Streptococcal Sequelae: ARF vs. PSGN

The two major non-suppurative immunological complications of Streptococcus pyogenes infection represent a cornerstone topic on board examinations. Differentiating their pathophysiology, latency, clinical presentation, and preventive potential is critical: NON-SUPPURATIVE SEQUELAE: THE CRUCIAL CONTRAST

ACUTE RHEUMATIC FEVER (ARF) POST-STREP GLOMERULONEPHRITIS (PSGN)
─────────────────────────── ────────────────────────────────────
Type II Hypersensitivity • Type III Hypersensitivity
Molecular Mimicry (M-Protein) • Immune Complex Deposition (Subepi)
Latency: 2 to 4 Weeks • Latency: 1-3 Wks (Pharynx) / 3-6 Wks (Skin)
Follows PHARYNGITIS ONLY • Follows PHARYNGITIS OR IMPETIGO
Mitral Regurg, Polyarthritis • Cola Urine, Edema, HTN (Nephritic)
Low C3 NOT typical • Marked Hypocomplementemia (Low C3)

PREVENTED BY ANTIBIOTICS! • NOT PREVENTED BY ANTIBIOTICS!

(Within 9 days of onset) (Antibiotics do NOT stop PSGN)
Acute Rheumatic Fever (ARF) & The Revised Jones Criteria

Pathogenesis : A systemic autoimmune disease provoked by an aberrant host immune response. Antibodies directed against the hypervariable M-protein of rheumatogenic GAS strains cross-react with human tissue antigens ( molecular mimicry )—specifically cardiac myosin, valve laminin, synovial antigens, and basal ganglia neuronal surface gangliosides.

Clinical Latency : Manifests 2 to 4 weeks following an untreated episode of GAS pharyngitis. ARF never follows streptococcal skin infections (impetigo) .

The Revised Jones Criteria : Confirmation requires proof of preceding GAS infection (positive RADT, positive throat culture, or rising anti-streptolysin O [ASO] / anti-DNase B titers) PLUS either 2 Major Criteria OR 1 Major + 2 Minor Criteria : REVISED JONES CRITERIA (ARF)

MAJOR CRITERIA (JONES) MINOR CRITERIA (FEVER)
──────────────────────────────── ──────────────────────────────
J - Joints: Migratory Polyarthritis F - Fever (>=38.5°C)
(Large joints; highly NSAID- E - ECG: Prolonged PR Interval
responsive) (Adjusted for age)
O - Carditis ('O' resembles heart) V - Valvulitis markers (elevated
(Pancarditis; mitral valve ESR >=60 mm/h or CRP >=3.0)
regurgitation most common) E - Elevated acute phase reactants
N - Nodules (Subcutaneous) R - Redness/Pain: Arthralgia
(Firm, painless, extensor) (Cannot use if arthritis is Major)
E - Erythema Marginatum
(Serpiginous, pink borders,
central clearing; non-pruritic)
S - Sydenham Chorea (St. Vitus)
(Rapid, involuntary movements,
facial grimacing, lability)

Secondary Prophylaxis : Patients with confirmed ARF require long-term secondary antimicrobial prophylaxis to prevent recurrent attacks and worsening rheumatic heart disease. The preferred regimen is intramuscular Benzathine Penicillin G 1.2 million units every 3 to 4 weeks . Duration ranges from 5 years (for ARF without carditis) up to 10 years or until age 21 to 40 (for ARF with residual valvular heart disease).

Post-Streptococcal Glomerulonephritis (PSGN)

Pathogenesis : An immune-complex-mediated (Type III) glomerulonephritis triggered by 'nephritogenic' strains of GAS bearing specific surface antigens (streptococcal pyrogenic exotoxin B [SPE B] or nephritis-associated plasmin receptor [NAPIr]). Circulating antigen-antibody complexes deposit within the glomerular basement membrane, producing subepithelial electron-dense 'humps', complement activation, and neutrophil infiltration.

Clinical Latency : Occurs 1 to 3 weeks following streptococcal pharyngitis , OR 3 to 6 weeks following streptococcal pyoderma / impetigo .

Clinical Manifestations : Classic acute nephritic syndrome :

Gross Hematuria : Dark, smoky, 'tea-colored' or 'coca-cola-colored' urine with dysmorphic red blood cells and red blood cell casts;

Edema : Characteristically periorbital edema prominent upon awakening, progressing to peripheral dependent edema;

Hypertension : Mild to moderate volume-overload arterial hypertension;

Oliguria & Proteinuria : Sub-nephrotic range proteinuria (<3.5 g/day).

Diagnostic Laboratory Findings : Profound hypocomplementemia with depressed serum C3 and normal or mildly reduced C4 (reflecting alternate complement pathway consumption; C3 normalizes within 6 to 8 weeks). Elevated ASO (post-pharyngitis) and anti-DNase B (post-impetigo).

CRITICAL BOARD FACT : Antibiotic treatment of the initial streptococcal pharyngitis or impetigo DOES NOT PREVENT the development of Post-Streptococcal Glomerulonephritis! (Antibiotics reduce organism spread to close contacts, but immune complexes have already formed or are destined to form). Management is purely supportive: dietary sodium and fluid restriction, loop diuretics (furosemide) for volume overload, and calcium channel blockers for hypertension. Prognosis in pediatric patients is outstanding (>95% achieve complete recovery without residual renal impairment).

Suppurative Complications & Urgent Differentials
Peritonsillar Abscess (Quinsy)

Pathology : A localized collection of pus in the potential space between the fibrous capsule of the palatine tonsil and the superior pharyngeal constrictor muscle. Typically polymicrobial, involving GAS, S. aureus , and oral anaerobes ( Fusobacterium , Prevotella ).

Clinical Triad : (1) Severe, progressive unilateral sore throat and odynophagia , (2) Trismus (inability to open the mouth due to inflammatory spasm of the internal pterygoid muscle), and (3) A muffled, guttural 'hot potato' voice .

Physical Examination : Marked unilateral swelling displacing the affected tonsil inferomedially, fullness and erythema of the ipsilateral anterior tonsillar pillar and soft palate, and deviation of the uvula toward the contralateral (unaffected) side . Ipsilateral referred otalgia and drooling are common.

Management : Emergent needle aspiration or surgical incision and drainage (I&D) performed under local anesthesia. Followed by broad-spectrum parenteral or oral antimicrobial therapy covering GAS and anaerobes ( amoxicillin-clavulanate 875/125 mg PO BID or clindamycin 300 mg PO TID for 14 days), alongside a single dose of systemic dexamethasone (10 mg IV/PO) to accelerate pain relief and resolve trismus.

Infectious Mononucleosis (EBV)

Etiology : Primary infection with Epstein-Barr virus (human herpesvirus 4).

Clinical Tetrad : Fever, severe exudative pharyngitis (with dense, confluent white-gray exudates), prominent symmetric posterior cervical and occipital lymphadenopathy , and profound fatigue. Splenomegaly is palpable in 50% to 60% of cases; hepatomegaly and palatal petechiae may be present.

Laboratory Evaluation : Peripheral blood smear reveals absolute lymphocytosis (>50% of white blood cells) with >10% atypical lymphocytes (reactive CD8+ cytotoxic T cells). Point-of-care heterophile antibody test ( Monospot ) is positive by week 2 of illness (may be falsely negative in the first week or in children <4 years; confirm with EBV-specific viral capsid antigen [VCA] IgM/IgG if suspicion is high).

The Aminopenicillin Rash : If an adolescent or young adult with acute EBV mononucleosis is mistakenly diagnosed with bacterial pharyngitis and prescribed amoxicillin or ampicillin , up to 70% to 90% develop a diffuse, copper-colored, pruritic maculopapular morbilliform rash 5 to 7 days into the antibiotic course. This is an immune-complex-mediated non-allergic drug eruption, NOT a true IgE-mediated penicillin allergy , and does not preclude future beta-lactam use.

Management : Supportive care (hydration, NSAIDs). Corticosteroids are reserved solely for impending upper airway obstruction from massive tonsillar hypertrophy or severe thrombocytopenia/hemolytic anemia. Strict avoidance of all contact sports and heavy lifting for at least 3 to 4 weeks from symptom onset is mandatory to prevent catastrophic traumatic splenic rupture .

Lemierre Syndrome (Post-Anginal Septicemia)

Pathogen : Fusobacterium necrophorum .

Pathogenesis : Begins as acute exudative pharyngitis in an otherwise healthy young adult, which invades the lateral pharyngeal space to cause septic thrombophlebitis of the internal jugular vein (IJV) , followed by hematogenous dissemination of septic emboli.

Clinical Presentation : High spiking fevers, rigors, unilateral tenderness and induration along the anterior border of the sternocleidomastoid muscle, and pleuritic chest pain with hemoptysis from cavitary septic pulmonary emboli .

Diagnosis & Treatment : Contrast-enhanced CT of the neck (demonstrating filling defects within the thrombosed internal jugular vein) and chest CT (multiple peripheral nodular cavitary infiltrates). Blood cultures confirm F. necrophorum . Requires prolonged intravenous antibiotic therapy with ampicillin-sulbactam (3 g IV q6h) or ceftriaxone plus metronidazole for 3 to 6 weeks.

High-Yield Board Pearls: Acute Pharyngitis

No Cough Rule : If an adult presents with a severe sore throat and fever, but has a persistent productive cough and runny nose, their Modified Centor score is <=1. Do NOT test for GAS and do NOT prescribe antibiotics.

Universal Susceptibility : Streptococcus pyogenes has never developed resistance to penicillin. Treatment failures are almost always due to non-adherence to the 10-day oral regimen, recurrent re-exposure, or co-colonization with beta-lactamase-producing flora.

The 9-Day Window : Antibiotics can be initiated up to 9 days after the onset of pharyngeal symptoms and still achieve full prevention of Acute Rheumatic Fever. There is no rush to treat empirically while awaiting backup throat culture results.

PSGN is NOT Preventable : Always remember that antibiotics do NOT prevent post-streptococcal glomerulonephritis. A patient who receives appropriate penicillin for strep throat can still present 2 weeks later with gross hematuria and hypertension.

EBV Rash Reassurance : The amoxicillin-induced rash in infectious mononucleosis does not represent a life-long drug allergy. Do not label the patient as 'penicillin-allergic' in their medical record without confirmatory testing.

Trismus Means Abscess : Severe sore throat accompanied by inability to fully open the jaw (trismus) and contralateral uvular deviation is a peritonsillar abscess until proven otherwise, mandating drainage.